日
関

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2014/02/05 15:15:46」(JST)

wiki en

Aclarubicin (INN) or Aclacinomycin A^[1] is an anthracycline drug^[2] that is used in the treatment of cancer. Soil bacteria Streptomyces galilaeus can produce aclarubicin.

References[edit]

^ Alcarubicin - PubChem
^ Jensen PB, Jensen PS, Demant EJ, et al. (October 1991). "Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II". Cancer Res. 51 (19): 5093–9. PMID 1655244.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 甲状腺分化癌：化学療法 differentiated thyroid cancer chemotherapy
2. 悪性腫瘍関連心膜疾患 pericardial disease associated with malignancy

English Journal

Low-dose cytarabine plus aclarubicin for patients with previously untreated acute myeloid leukemia or high-risk myelodysplastic syndrome ineligible for standard-dose cytarabine plus anthracycline.

Fukushima T, Kawabata H, Sawaki T, Satoh T, Nakamura T, Iwao H, Nakajima A, Sakai T, Miki M, Fujita Y, Tanaka M, Kawanami T, Masaki Y, Okazaki T, Umehara H.SourceDepartment of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan. tfukus@kanazawa-med.ac.jp
Anticancer research.Anticancer Res.2012 Apr;32(4):1347-53.
BACKGROUND: In order to assess the role of the combination of low-dose cytarabine (Ara-C) plus aclarubicin (CA) in remission induction for patients with untreated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS), we retrospectively analyzed the efficacy and safety of CA.PATIE
PMID 22493369

In vitro antifungal activity of DNA topoisomerase inhibitors.

Steverding D, Evans P, Msika L, Riley B, Wallington J, Schelenz S.SourceNorwich Medical School, University of East Anglia, Norwich, UK. dsteverding@hotmail.com
Medical mycology : official publication of the International Society for Human and Animal Mycology.Med Mycol.2012 Apr;50(3):333-6. Epub 2011 Sep 22.
In this paper we report the results of the study of the in vitro effect of eight anticancer DNA topoisomerase inhibitors on the growth of Aspergillus fumigatus, A. niger, Candida glabrata and Cryptococcus neoformans. Only one compound, idarubicin, displayed promising antifungal activity against A. n
PMID 21939347

Japanese Journal

臍帯血移植後再発に対してアザシチジン投与が有効であった骨髄異形成症候群

上田里美,宮腰重三郎,遅塚明貴,小島理絵,小笠原壽恵,宮本鋼
臨床血液 54(12), 2177-2181, 2013
72歳男性。2009年7月，立ちくらみを主訴に当院受診，骨髄異形成症候群(MDS) RAEB-2と診断された。CA療法を1回，low-dose Ara-Cを2回施行し，第一寛解期の2010年1月に臍帯血移植を施行した。2011年9月再発し，アザシチジン(AZA) 100 mg/日7日間皮下注射を開始した。血液状態をみながらAZA 100 mg/日7ないしは5日間投与を計9コース施行し，再発後一年経 …
NAID 130004501796

CAG-GO therapy for patients with relapsed or primary refractory CD33-positive acute myelogenous leukemia

高橋渉,仲村祐子,田所治朗,半田智幸,新井ほのか,鴇田勝哉,磯桐子,鶴見茂治,佐々木光,牧和宏,三谷絹子
臨床血液 53(1), 71-77, 2012
… We previously tested a less toxic CAG regimen consisting of low-dose cytarabine, aclarubicin and granulocyte-colony stimulating factor for the treatment of patients with relapsed or refractory myeloid malignancies or elderly patients with untreated ones, obtaining a satisfactory complete remission rate of 62%. …
NAID 130004501565

アクラルビシン封入PLGAナノスフェアの門脈内投与によるラット転移性肝がんに対する治療効果

冨山成章,大河内秀昭,中村千鶴子,中野眞汎
医療薬学 34(1), 40-47, 2008-01-10
… We investigated the therapeutic effect of poly (lactic-co-glycolic) acid (PLGA) nanospheres containing aclarubicin on hepatic metastases in rats following injection of the nanospheres via the portal vein. … The aclarubicin-containing PLGA nanospheres were prepared by a solvent evaporation method. …
NAID 110006546898

Related Pictures

★リンクテーブル★

リンク元	「アクラルビシン」「ACR」
拡張検索	「aclarubicin hydrochloride」

「アクラルビシン」

Aclarubicin
Systematic (IUPAC) name
	(1S,2S,4R)-methyl 4-(((2S,5R,6R)-4-(dimethylamino)-5-(((1S,3R,4S)-3-hydroxy-5-methyl-4-(((2S,6R)-6-methyl-5-oxotetrahydro-2H-pyran-2-yl)oxy)cyclohexyl)oxy)-6-methyltetrahydro-2H-pyran-2-yl)oxy)-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracene-1-carboxylate
Clinical data
AHFS/Drugs.com	International Drug Names
Legal status	℞ Prescription only
Routes	IV
Identifiers
CAS number	57576-44-0
ATC code	L01DB04
PubChem	CID 42474
ChemSpider	1931
UNII	74KXF8I502
KEGG	D02756
ChEBI	CHEBI:74619
ChEMBL	CHEMBL1697719
Chemical data
Formula	C42H53NO15
Mol. mass	811.86 g/mol
	SMILES CCC1(CC(C2=C(C1C(=O)OC)C=C3C(=C2O)C(=O)C4=C(C3=O)C=CC=C4O)OC5CC(C(C(O5)C)OC6CC(C(C(O6)C)OC7CCC(=O)C(O7)C)O)N(C)C)O;
	InChI InChI=1S/C42H53NO15/c1-8-42(51)17-28(33-22(35(42)41(50)52-7)14-23-34(38(33)49)37(48)32-21(36(23)47)10-9-11-26(32)45)56-30-15-24(43(5)6)39(19(3)54-30)58-31-16-27(46)40(20(4)55-31)57-29-13-12-25(44)18(2)53-29/h9-11,14,18-20,24,27-31,35,39-40,45-46,49,51H,8,12-13,15-17H2,1-7H3 ; Key:USZYSDMBJDPRIF-UHFFFAOYSA-N ;
(what is this?) (verify)